Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 1999

View Archived Issues

Droloxifene plus PGE2 effectively restores and maintains bone mass

Fomepizole, an effective antidote to ethylene glycol poisoning

BioChem Pharma licenses antiviral technology from OSI Pharmaceuticals

Megabios and GeneMedicine complete merger; combined company to be named Valentis

AltaRex updates OvaRex MAb and BrevaRex MAb clinical progress

Pharmacyclics updates Antrin photoangioplasty trial interim results

Bioniche technology offers synergistic benefits in cancer therapy

Halving dose of Preveon does not reduce its efficacy in HIV

More positive clinical data on new antibiotic linezolid presented at ECCMID

Algos: Q4 and year-end 1998 highlights

Enrollment completed for trial of InKine purgative tablets

Function of anandamide discovered

Iomed to develop drugs to treat local inflammation, ocular disease and pain control

Structurally distinct 5-HT ligands for depression, anxiety discovered at SB

Patent issued to Pfizer for NPY antagonist series

Novel series from Egis with muscle relaxant, neuroprotective and anticonvulsant activity

Novel quinolone antibacterial agents discovered at Korean research institute

New Sustiva clinical data reported at European congress

New candidate for treatment of atopic dermatitis synthesized at Nissan Chemical

U.S. patent issues to Vivus for second-generation ED therapeutic

British Biotech completes strategic review, defines new priorities

TEI-9874, an allergen-specific IgE production inhibitor for treatment of allergic asthma

FDA approves Duramed's Cenestin for treatment of menopause symptoms

CPMP opinion favors approval of Glaxo Wellcome's Ziagen

FDA grants world's first approval for a single-isomer bronchodilator

Biora creates new subsidiary to develop products for use outside the oral cavity

More ACS news: SmithKline Beecham continues to research CXCR2 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...